Semble has successfully closed a £11.6m Series B funding round, marking a significant step in its overseas expansion ambitions.
- The company’s innovative clinical system aims to replace outdated technology, improving efficiency for healthcare providers.
- CEO Christoph Lippuner emphasizes the importance of workflow automation in enhancing healthcare services.
- The funding round was led by Mercia Ventures with participation from Octopus Ventures, Smedvig Ventures, and Triple Point.
- Semble has raised a total of $27m to date, demonstrating strong investor confidence and market potential.
London-based health tech firm Semble has secured £11.6m in its Series B funding round, marking a crucial milestone in its plan to expand internationally. The funding, equivalent to $15m, was spearheaded by Mercia Ventures, alongside notable contributions from Octopus Ventures, Smedvig Ventures, and Triple Point.
Semble is tackling inefficiencies in healthcare IT systems, a significant issue highlighted by the British Medical Association, which notes that outdated systems result in over 13 million lost working hours annually for doctors in England. Semble’s advanced clinical platform is poised to address these challenges, offering solutions that automate tasks, securely exchange patient data, and seamlessly integrate with third-party systems.
CEO Christoph Lippuner, together with co-founder Mikael Landau, initiated Semble in 2018 after successfully selling their previous venture, Orogo, to Just Eat. Lippuner underscores the mission to empower healthcare professionals by modernizing their technology tools. He stresses that their ongoing investments in workflow automation and system integrations are shaping a more interconnected healthcare environment.
The funding achievement reaffirms the founders’ strategic vision and the firm’s rapid growth trajectory. Alex Gwyther of Mercia Ventures articulates that the healthcare industry’s dependency on legacy systems poses substantial risks, but he remains optimistic about Semble’s capacity to leverage this opportunity given the founders’ insight into the sector.
Having previously raised $8.3m in a Series A round in September 2021, Semble, initially named Heydoc, has now amassed total funding of $27m. This financial backing is not only a testament to its potential but also a reflection of investors’ robust belief in its transformative agenda.
Semble’s recent funding success underscores its promising role in revolutionizing healthcare technology.
